The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis

Annals of the Rheumatic Diseases

Volumn 66, Issue 10, 2007, Pages 1345-1349

  Chinoy, Hector ^b   Fertig, Noreen ^c   Oddis, Chester V ^c   Ollier, William E R ^b   Cooper, Robert G ^a,b  

^a HOPE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; RIBONUCLEOPROTEIN ANTIBODY;

ADULT; AGED; ARTICLE; CANCER; CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOASSAY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMYOSITIS; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CONNECTIVE TISSUE DISEASES; CROSS-SECTIONAL STUDIES; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS; NEOPLASMS; POLYMYOSITIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 34548566557     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.068502     Document Type: Article

References (26)

1. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis, a population-based study. N Engl J Med 1992;326:363-7.
2. Chow WH, Gridley G, Mellemkjaer L, Mclaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995;6:9-13.
3. Airio A, Pukkala E, lsomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995;22:1300-3.
4. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy, a population-based cohort study. Ann Intern Med 2001;134:1087-95.
5. Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 2002;4:415-26.
6. Troyanov Y, Targoff IN, Tremblay JL, Goulet Jr, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-49.
7. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
8. Brouwer R, Hengstman GJ, Vree EW, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
9. Chinoy H, Salway F, Fertig N, Shephard N, Tait Bd, Thomson W, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006;8:R13.
10. O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -Drb1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006;85:111-27.
11. Levine SM, Rosen A, Casciola-Rosen LA. Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2003;15:708-13.
12. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep 2003;5:425- 30.
13. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005;201:591-601.
14. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al. A novel autoantibody to a 155-kD protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682-9.
15. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007;46:25-8.
16. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-47.
17. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
18. Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
20. Preliminary Criteria for the Classification of Systemic Sclerosis (Scleroderma). Subcommittee lor Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
21. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria tor the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
23. Alarcon-Segovia D. Mixed connective tissue disease and overlap syndromes. Clin Dermatol 1994;12:309-16.
24. Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006;65:242-5.
25. Targoff I, Shamim E, Sherry D, Wallace C, Haftel H, Miller F, et al. A novel dermatomyositis (DM)-associated autoantibody directed against a 155 kD protein [Abstract]. Arthritis Rheum 2000;43:S175.
26. Targoff IN, Trieu EP, Levy-Nato M, Prasertsuntarasai T, Miller FW. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-γ) in dermatomyositis [Abstract], Arthritis Rheum 2006;54:S518.